Market Cap
$222.17B
P/E Ratio
32.36
52W High
$647.00
52W Low
$435.27
Quality Score
TMO scores 72/100 (B) — dividend safety is the strongest factor, valuation the weakest.
72
/ 100
See the full 7-factor breakdown with PRO.
UpgradeAI Technical Interpretation
PRO turns TMO's RSI, MACD, moving averages, and Bollinger Bands into a plain-English read on trend, momentum, and volatility - context, not predictions.
Upgrade to PROAI “Why Did It Move?”
Get a ranked, evidence-grounded read on what's likely driving TMO's move today — news, earnings, analyst activity, sector context, and technicals combined.
Upgrade to PROAnalyst Ratings28 analysts
Consensus & price targets via Yahoo Finance & Financial Modeling Prep. Not investment advice.
AI Fair Value Estimate
Get an AI analyst's take on whether TMO looks cheap or expensive — a fair-value range with plain-English reasoning, in one click.
Upgrade to PROAI Earnings Preview
Next report 2026-10-21 · in 50 days
Consensus estimates
EPS
$6.40
Revenue
$11.95B
Recent EPS surprises
Unlock the AI preview for TMO
Get an AI analyst's read on the setup, what to watch, and risks heading into the print.
Upgrade to PROUnlock the post-earnings recap for TMO
Get an AI analyst's read on how the report went and how the stock reacted.
Upgrade to PRODividendQuarterly
Forward yield
0.31%
Annual / share
$1.88
Last ex-date
Jun 15, 2026
Last payment
Oct 15, 2026
Recent payments
Forward annual dividend from the declared rate (or latest payment × frequency) · via Yahoo Finance & Financial Modeling Prep.
AI Dividend Safety
Get an AI read on whether TMO's dividend looks sustainable — earnings coverage, payout history, and the risks worth researching.
Upgrade to PROInsider Trading50 recent filings
Buys
6
Sells
44
Reported value
$48.67M
| Date | Insider | Type | Shares | Price | Value | Owned |
|---|---|---|---|---|---|---|
| Aug 19, 2026 | BRITT, LISA P. Sr. VP and Chief HR Officer | Sell | 11,440 | $0.00 | $0.00 | - |
| Aug 19, 2026 | BRITT, LISA P. Sr. VP and Chief HR Officer | Buy | 11,440 | $418.32 | $4.79M | - |
| Aug 19, 2026 | BRITT, LISA P. Sr. VP and Chief HR Officer | Sell | 11,440 | $613.12 | $7.01M | - |
| Aug 11, 2026 | SHAFER, MICHAEL D Executive Vice President | Sell | 14,300 | $600.00 | $8.58M | - |
| Aug 11, 2026 | SHAFER, MICHAEL D Executive Vice President | Buy | 14,300 | $418.32 | $5.98M | - |
| Aug 11, 2026 | SHAFER, MICHAEL D Executive Vice President | Sell | 11,200 | $600.00 | $6.72M | - |
| Aug 11, 2026 | SHAFER, MICHAEL D Executive Vice President | Buy | 11,200 | $309.63 | $3.47M | - |
| Aug 11, 2026 | SHAFER, MICHAEL D Executive Vice President | Sell | 14,300 | $0.00 | $0.00 | - |
| Aug 11, 2026 | SHAFER, MICHAEL D Executive Vice President | Sell | 11,200 | $0.00 | $0.00 | - |
| Aug 7, 2026 | CASPER, MARC N Director, Chairman & CEO | Sell | 228 | $587.64 | $133,981.92 | - |
| Aug 7, 2026 | CASPER, MARC N Director, Chairman & CEO | Sell | 1,035 | $584.41 | $604,864.35 | - |
| Aug 7, 2026 | CASPER, MARC N Director, Chairman & CEO | Sell | 6 | $577.37 | $3,464.22 | - |
| Aug 7, 2026 | CASPER, MARC N Director, Chairman & CEO | Sell | 4 | $579.26 | $2,317.04 | - |
| Aug 7, 2026 | CASPER, MARC N Director, Chairman & CEO | Sell | 2 | $579.27 | $1,158.54 | - |
| Aug 7, 2026 | CASPER, MARC N Director, Chairman & CEO | Sell | 4 | $580.71 | $2,322.84 | - |
| Aug 7, 2026 | CASPER, MARC N Director, Chairman & CEO | Sell | 3 | $580.72 | $1,742.16 | - |
| Aug 7, 2026 | CASPER, MARC N Director, Chairman & CEO | Sell | 5 | $581.85 | $2,909.25 | - |
| Aug 7, 2026 | CASPER, MARC N Director, Chairman & CEO | Sell | 2 | $581.86 | $1,163.72 | - |
| Aug 7, 2026 | CASPER, MARC N Director, Chairman & CEO | Sell | 18 | $583.37 | $10,500.66 | - |
| Aug 7, 2026 | CASPER, MARC N Director, Chairman & CEO | Sell | 63 | $584.40 | $36,817.20 | - |
| Aug 7, 2026 | CASPER, MARC N Director, Chairman & CEO | Sell | 30 | $585.42 | $17,562.60 | - |
| Aug 7, 2026 | CASPER, MARC N Director, Chairman & CEO | Sell | 117 | $593.31 | $69,417.27 | - |
| Aug 7, 2026 | CASPER, MARC N Director, Chairman & CEO | Sell | 495 | $590.78 | $292,436.10 | - |
| Aug 7, 2026 | CASPER, MARC N Director, Chairman & CEO | Sell | 522 | $589.52 | $307,729.44 | - |
| Aug 7, 2026 | CASPER, MARC N Director, Chairman & CEO | Sell | 945 | $586.52 | $554,261.40 | - |
| Aug 7, 2026 | CASPER, MARC N Director, Chairman & CEO | Sell | 530 | $585.44 | $310,283.20 | - |
| Aug 7, 2026 | CASPER, MARC N Director, Chairman & CEO | Sell | 58 | $586.53 | $34,018.74 | - |
| Aug 7, 2026 | CASPER, MARC N Director, Chairman & CEO | Sell | 12 | $587.64 | $7,051.68 | - |
| Aug 7, 2026 | CASPER, MARC N Director, Chairman & CEO | Sell | 32 | $589.51 | $18,864.32 | - |
| Aug 7, 2026 | CASPER, MARC N Director, Chairman & CEO | Sell | 29 | $590.77 | $17,132.33 | - |
| Aug 7, 2026 | CASPER, MARC N Director, Chairman & CEO | Sell | 7 | $593.32 | $4,153.24 | - |
| Aug 7, 2026 | CASPER, MARC N Director, Chairman & CEO | Sell | 94 | $577.37 | $54,272.78 | - |
| Aug 7, 2026 | CASPER, MARC N Director, Chairman & CEO | Sell | 114 | $579.26 | $66,035.64 | - |
| Aug 7, 2026 | CASPER, MARC N Director, Chairman & CEO | Sell | 113 | $580.71 | $65,620.23 | - |
| Aug 7, 2026 | CASPER, MARC N Director, Chairman & CEO | Sell | 113 | $581.85 | $65,749.05 | - |
| Aug 7, 2026 | CASPER, MARC N Director, Chairman & CEO | Sell | 275 | $0.00 | $0.00 | - |
| Aug 7, 2026 | CASPER, MARC N Director, Chairman & CEO | Sell | 302 | $583.35 | $176,171.70 | - |
| Aug 7, 2026 | HOLMES, JOSEPH R. VP & Chief Accounting Officer | Buy | 420 | $309.63 | $130,044.60 | - |
| Aug 7, 2026 | HOLMES, JOSEPH R. VP & Chief Accounting Officer | Sell | 420 | $584.81 | $245,620.20 | - |
| Aug 7, 2026 | HOLMES, JOSEPH R. VP & Chief Accounting Officer | Sell | 420 | $0.00 | $0.00 | - |
| Aug 7, 2026 | CASPER, MARC N Director, Chairman & CEO | Buy | 275 | $309.63 | $85,148.25 | - |
| Aug 6, 2026 | CASPER, MARC N Director, Chairman & CEO | Sell | 1,631 | $572.43 | $933,633.33 | - |
| Aug 6, 2026 | CASPER, MARC N Director, Chairman & CEO | Sell | 127 | $580.01 | $73,661.27 | - |
| Aug 6, 2026 | CASPER, MARC N Director, Chairman & CEO | Sell | 2,164 | $575.46 | $1.25M | - |
| Aug 6, 2026 | CASPER, MARC N Director, Chairman & CEO | Sell | 119 | $578.93 | $68,892.67 | - |
| Aug 6, 2026 | CASPER, MARC N Director, Chairman & CEO | Sell | 361 | $577.57 | $208,502.77 | - |
| Aug 6, 2026 | CASPER, MARC N Director, Chairman & CEO | Sell | 225 | $576.09 | $129,620.25 | - |
| Aug 6, 2026 | CASPER, MARC N Director, Chairman & CEO | Sell | 1,617 | $574.40 | $928,804.80 | - |
| Aug 6, 2026 | BRITT, LISA P. Sr. VP and Chief HR Officer | Buy | 5,850 | $309.63 | $1.81M | - |
| Aug 6, 2026 | BRITT, LISA P. Sr. VP and Chief HR Officer | Sell | 5,850 | $580.00 | $3.39M | - |
Insider transactions via Alpha Vantage with SEC EDGAR fallback. Data can include grants, planned sales, and administrative filings; this is not investment advice.
AI Stock Analysis
Unlock an in-depth, balanced bull/bear breakdown of TMO — catalysts, risks, and a plain-language read on the fundamentals.
Upgrade to PROInvestor Copilot Notebook
Keep a thesis on TMO
Save your buy/watch/avoid rationale, track it over time, and get an AI read on whether the data still backs it up.
Upgrade to PROInvestment Thesis Timeline
See TMO's full timeline
Earnings surprises, news catalysts, insider activity, and your own notebook events — one dated, classified feed.
Upgrade to PRODeeper technical charting, indicators, and pattern tools that complement XMarketPro's research.
Open advanced chartsSponsored partner — XMarketPro may receive compensation if you sign up or purchase through this link. Partner compensation does not influence XMarketPro's analysis, ratings, or research conclusions.
Automated technical analysis, charting, and pattern recognition for active traders.
Explore automated technical analysisSponsored partner — XMarketPro may receive compensation if you sign up or purchase through this link. Partner compensation does not influence XMarketPro's analysis, ratings, or research conclusions.
Another independent research perspective to compare against XMarketPro's own analysis.
Compare with additional researchSponsored partner — XMarketPro may receive compensation if you sign up or purchase through this link. Partner compensation does not influence XMarketPro's analysis, ratings, or research conclusions.
A well-established U.S. brokerage for investors moving from research into execution.
Explore brokerage optionsSponsored partner — XMarketPro may receive compensation if you sign up or purchase through this link. Partner compensation does not influence XMarketPro's analysis, ratings, or research conclusions.
About Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
Visit thermofisher.comKey Statistics
- Open
- $619.00
- Prev Close
- $617.10
- Day High
- $621.00
- Day Low
- $600.54
- Volume
- 752K
- Market Cap
- $222.17B
- P/E Ratio
- 32.36
- EPS
- $18.57
- Beta
- 0.85
- Dividend Yield
- +0.30%
- 52W High
- $647.00
- 52W Low
- $435.27
- Analyst Target
- —